Shanthi Rexaline

Shanthi is a contributor to InvestorPlace.com and works as a Staff Writer with Benzinga. Equipped with a Bachelor’s degree in Agriculture and an MBA with specialization in finance and marketing, she has about two decades of experience in financial reporting and analysis, and specializes in the biopharma and EV sectors.

Recent Articles

Everyone Is Buzzing About the Tesla Cybertruck: What We Know Today

By Shanthi Rexaline

After multiple delays Tesla's Cybertruck may finally be on roads by next year. It remains to be seen whether the EV giant keeps the timeline this time around.

7 Hypergrowth Tech Stocks to Buy Before They Rocket

By Shanthi Rexaline

Key to successful investing is identifying stocks of high-growth businesses that are available at affordable prices. With the recent market downturn, some of the tech plays are once again turning attractive.

Origin Agritech’s Corn Contract Sends Stock Soaring; But It’s Not a SEED to Plant Yet

By Shanthi Rexaline

Origin Agritech's rally on the back of contract wins for its fortified corn alone cannot guarantee redemption for the stock. The fundamental story of the genetically-modified crop and seed manufacturer is far from convincing.

Costco Is an Absolute Buy. Here’s Why.

By Shanthi Rexaline

As the U.S. economy stutters, COST stock could end the search for recession-proof stocks, which has built up a reputation as a defensive play.

7 Biotech Stocks to Buy With Key Catalysts for April

By Shanthi Rexaline

Biotech stocks are very sensitive to some key catalysts such as the FDA decision date, aka PDUFA date, clinical readouts/presentations and Adcom meeting. The month of April will see some companies belonging to the sector seeing some of these make-or-break catalysts.

Load More